About me
David Campard is CMC Regulatory Affairs Specialist and leads multiple early development projects at Novo Nordisk for cell and gene therapy products (CGTPs). In this role, he set the regulatory strategy for CMC development of CGTPs in alignment with other areas (clinical, non-clinical, devices), engages interactions with Health Authorities at different clinical/product development phases, implements the strategy by coordinating regulatory submissions (briefing documents, qIMPD/IND, responses to questions). David holds a PhD in Cell Biology and has a researcher background in stem cells. He has more than 13 years of experience in CMC RA for various modalities through clinical studies, marketing authorization and life cycle of licensed products
